{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:33:38Z","timestamp":1793226818177,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cmi.2026.09.036","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:52:04Z","timestamp":1791672724000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: \u2018Pharmacokinetics, target attainment, and outcomes of piperacillin\/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis\u2019 by Chiriac et al."],"prefix":"10.1016","author":[{"given":"Pier Giorgio","family":"Cojutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.09.036_bib1","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.cmi.2026.04.010","article-title":"Pharmacokinetics, target attainment, and outcomes of piperacillin\/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: A retrospective analysis","volume":"32","author":"Chiriac","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.09.036_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01404-23","article-title":"Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin\/tazobactam against extended spectrum beta-lactamase producing Enterobacterales","volume":"68","author":"Cojutti","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.09.036_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cmi.2026.09.036_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/34.4.555","article-title":"Inhibition of the renal excretion of tazobactam by piperacillin","volume":"34","author":"Komuro","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.09.036_bib5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/antibiotics12121736","volume":"12","author":"Gatti","year":"2023","journal-title":"Antibiotics (Basel)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26005720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:12:55Z","timestamp":1793225575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26005720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"alternative-id":["S1198743X26005720"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.09.036","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: \u2018Pharmacokinetics, target attainment, and outcomes of piperacillin\/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis\u2019 by Chiriac et al.","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}